Boeing Valuation
Is BACL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BACL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BACL (CLP174559) is trading below our estimate of fair value (CLP298111.16)
Significantly Below Fair Value: BACL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BACL?
Key metric: As BACL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BACL's PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | US$73.29b |
| Market Cap | US$114.39b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | -40.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BACL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.1x | ||
AIR Airbus | 1.6x | 10.2% | €109.3b |
LMT Lockheed Martin | 1.7x | 3.2% | US$128.5b |
SAF Safran | 3.6x | 10.7% | €91.7b |
GD General Dynamics | 1.7x | 4.7% | US$77.4b |
BACL Boeing | 1.6x | 13.3% | CL$114.4b |
Price-To-Sales vs Peers: BACL is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (2.1x).
Price to Sales Ratio vs Industry
How does BACL's PS Ratio compare vs other companies in the Global Aerospace & Defense Industry?
| 46 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 46 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: BACL is good value based on its Price-To-Sales Ratio (1.6x) compared to the Global Aerospace & Defense industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is BACL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BACL's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CL$174,559.00 | CL$177,891.23 +1.9% | 17.1% | CL$244,070.00 | CL$82,983.80 | n/a | 24 |
| Nov ’25 | CL$174,559.00 | CL$175,503.78 +0.5% | 17.1% | CL$240,245.00 | CL$82,644.28 | n/a | 24 |
| Oct ’25 | CL$174,559.00 | CL$189,852.51 +8.8% | 14.8% | CL$248,663.25 | CL$99,465.30 | n/a | 24 |
| Sep ’25 | CL$174,559.00 | CL$203,721.20 +16.7% | 10.8% | CL$254,325.50 | CL$171,091.70 | n/a | 25 |
| Aug ’25 | CL$174,559.00 | CL$210,255.94 +20.4% | 11.2% | CL$261,912.75 | CL$166,671.75 | n/a | 25 |
| Jul ’25 | CL$174,559.00 | CL$204,078.95 +16.9% | 11.8% | CL$257,342.25 | CL$163,763.25 | n/a | 25 |
| Jun ’25 | CL$174,559.00 | CL$204,652.54 +17.2% | 13.9% | CL$273,462.00 | CL$159,519.50 | n/a | 27 |
| May ’25 | CL$174,559.00 | CL$216,882.96 +24.2% | 16.1% | CL$288,114.00 | CL$134,453.20 | n/a | 28 |
| Apr ’25 | CL$174,559.00 | CL$240,045.45 +37.5% | 10.5% | CL$295,470.00 | CL$196,980.00 | n/a | 28 |
| Mar ’25 | CL$195,445.00 | CL$253,211.21 +29.6% | 9.7% | CL$294,060.00 | CL$196,040.00 | n/a | 28 |
| Feb ’25 | CL$195,445.00 | CL$240,570.81 +23.1% | 10.7% | CL$293,605.20 | CL$177,095.20 | n/a | 29 |
| Jan ’25 | CL$165,000.00 | CL$238,732.07 +44.7% | 12.2% | CL$285,200.00 | CL$169,337.50 | n/a | 29 |
| Dec ’24 | CL$165,000.00 | CL$212,635.00 +28.9% | 9.6% | CL$257,184.00 | CL$162,883.20 | n/a | 29 |
| Nov ’24 | CL$165,000.00 | CL$215,487.67 +30.6% | 9.9% | CL$246,570.50 | CL$170,357.80 | CL$174,559.00 | 27 |
| Oct ’24 | CL$165,000.00 | CL$231,604.40 +40.4% | 10.8% | CL$282,478.20 | CL$185,888.88 | CL$174,559.00 | 23 |
| Sep ’24 | CL$165,000.00 | CL$219,395.54 +33.0% | 10.1% | CL$265,208.10 | CL$179,657.10 | CL$174,559.00 | 22 |
| Aug ’24 | CL$165,000.00 | CL$213,228.19 +29.2% | 10.6% | CL$260,586.00 | CL$176,526.00 | CL$174,559.00 | 21 |
| Jul ’24 | CL$165,000.00 | CL$188,374.86 +14.2% | 9.8% | CL$234,972.32 | CL$145,343.70 | CL$174,559.00 | 24 |
| Jun ’24 | CL$165,000.00 | CL$190,664.03 +15.6% | 9.3% | CL$235,643.07 | CL$145,758.60 | CL$174,559.00 | 22 |
| May ’24 | CL$165,000.00 | CL$186,866.57 +13.3% | 11.5% | CL$233,425.65 | CL$130,830.67 | CL$174,559.00 | 21 |
| Apr ’24 | CL$165,000.00 | CL$180,962.85 +9.7% | 10.2% | CL$206,923.41 | CL$129,307.31 | CL$174,559.00 | 20 |
| Mar ’24 | CL$175,260.00 | CL$182,619.92 +4.2% | 10.2% | CL$209,178.45 | CL$130,716.50 | CL$195,445.00 | 21 |
| Feb ’24 | CL$175,260.00 | CL$182,014.54 +3.9% | 12.3% | CL$210,757.50 | CL$129,200.00 | CL$195,445.00 | 20 |
| Jan ’24 | CL$164,060.00 | CL$178,108.98 +8.6% | 14.3% | CL$218,372.50 | CL$105,692.29 | CL$165,000.00 | 20 |
| Dec ’23 | CL$154,980.00 | CL$180,187.15 +16.3% | 15.7% | CL$234,307.50 | CL$113,404.83 | CL$165,000.00 | 20 |
| Nov ’23 | CL$126,580.00 | CL$179,014.28 +41.4% | 17.3% | CL$236,487.50 | CL$92,703.10 | CL$165,000.00 | 21 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Echeverría Izquierdo
CL$97.2b
Engages in the engineering and construction activities in Chile.
EISA
CL$162.20
7D
3.0%
1Y
28.2%
Compañía Agropecuaria Copeval
CL$30.5b
Distributes and markets agricultural machinery and products.
COPEVAL
CL$732.60
7D
0%
1Y
0%
Navarino
CL$212.8b
Through its subsidiaries, manufactures and sells steel parts for mining and grinding balls in Chile and internationally.
NAVARINO
CL$1,500.00
7D
0%
1Y
-7.2%